“…Unfortunately, the commercial impact of PHA-based bioplastics has been historically prohibited by their higher production costs than oil-derived plastics (Chen et al, 2020). However, more efficient PHAs production processes have been devised through the rational design of phaCAB biosynthetic pathways (Hiroe et al, 2012;Kelwick et al, 2015b;Li et al, 2016;Tao et al, 2017;Zhang X. et al, 2019), key metabolite recycling processes (e.g., Acetyl-CoA) (Matsumoto et al, 2013;Beckers et al, 2016), alternative microbial production hosts (e.g., Halomonas sp., Tan et al, 2011) and the use of industrially sourced, low-cost feedstocks (e.g., whey permeate) (Wong and Lee, 1998;Ahn et al, 2000;Kim, 2000;Nikel et al, 2006;Cui et al, 2016;Nielsen et al, 2017). Interestingly, several of these microbial PHAs production strategies are also compatible with cell-free synthetic biology reactions.…”